FLGT - Fulgent Genetics to acquire Inform Diagnostics for $170M raises Q1 guidance

Fulgent Genetics (NASDAQ:FLGT) to acquire Inform Diagnostics, a national independent pathology laboratory based in Irving, Texas, and a portfolio company of Avista Capital Partners. Total purchase price of ~$170M, closing expected in Q2. For Q1, anticipates total revenue to be ~$300M compared to previous guidance of $245M. (consensus $244.65M) Also, company now expects core revenue for FY 2022 to be ~$175M, compared to previous guidance of $120M. Core revenue excluding COVID-19 NGS testing to be at least $22M, consistent with previous guidance. Further analysis on the stock by contributor who writes Now The Going Could Get Much Tougher

For further details see:

Fulgent Genetics to acquire Inform Diagnostics for $170M, raises Q1 guidance